Glenmark Pharmaceuticals is currently trading at RS. 2045.75, up by 55.15 points or 2.77% from its previous closing of RS. 1990.60 on the BSE.

The stock opened at RS. 1990.60 and touched a high of RS. 2055.15 and a low of RS. 1990.60. So far, 15447 shares have been traded on the counter.

The BSE group 'A' stock with a face value of RS. 1 recorded a 52-week high of RS. 2286.15 on July 11, 2025, and a 52-week low of RS. 1274.70 on February 28, 2025. Over the last week, the stock has moved between RS. 2055.15 and RS. 1903.50. The company’s current market capitalization stands at RS. 57879.39 crore.

Promoter shareholding in the company is at 46.65%, while institutions hold 38.30% and non-institutions hold 15.06%.

On the R&D front, Glenmark Pharmaceuticals has initiated a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, targeting patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting. The company has already received approval from the Drugs Controller General of India (DCGI) to begin patient enrolment and dosing.

In addition, Glenmark has submitted a Clinical Trial Application (CTA) in Russia and is preparing to expand clinical trial sites to Brazil and Mexico. This pivotal, randomized, multi-center Phase 3 trial will assess the efficacy, safety, pharmacokinetics, and immunogenicity of Envafolimab in patients with resectable Stage IIIA and IIIB (N2) NSCLC. A parallel Phase 3 study sponsored by 3D Medicines Inc. has been underway in China since December 2023.

Lung cancer remains the leading cause of cancer-related deaths worldwide, with NSCLC accounting for 80–85% of cases. Around 20–30% are diagnosed at Stage III, where five-year survival remains low—about 36% for Stage IIIA and 26% for Stage IIIB. Envafolimab aims to provide an innovative, accessible immunotherapy option to improve survival outcomes in such patients.

Glenmark Pharmaceuticals is a research-driven global pharmaceutical company with a strong presence in Generics, Specialty, and OTC segments, operating in over 50 countries.